Please login to the form below

Not currently logged in
Email:
Password:

SMC gives green light for BMS’ Opdivo

Scotland will be first UK country to access the drug after NICE refusal

Bristol-Myers SquibbLung cancer patients in Scotland will be the first in the UK to access Bristol-Myers Squibb's immunotherapy Opdivo via the NHS, following a recommendation by the Scottish Medicines Consortium (SMC).

It is a boost for the manufacturer after NICE last week refused to recommend Opdivo (nivolumab) in England as a treatment for kidney cancer.

The PD-1 immune checkpoint inhibitor extends overall survival in post-chemotherapy patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) - a particularly aggressive sub-type of lung cancer with limited treatment options.

NSCLC patients tend to be diagnosed in the later stages of the disease, which typically has a poor prognosis with an overall survival time of six months.

The additional three to four months' survival time and improved quality of life that Opdivo can offer is therefore a significant gain.

Meanwhile, the SMC also approved Pfizer's lung cancer therapy Xalkori (crizotinib) for patients with ALK-positive NSCLC.

Average survival for this rare sub-type is less than one year, and generally affects a younger age group than other lung cancers. Pfizer's oral treatment can delay disease progression for an average of four months.

The ALK inhibitor has been approved as second-line therapy for ALK-positive NSCLC patients since 2012 and is now available in more than 85 countries worldwide.

It was approved for a label update by the European Commission in December last year, authorising the drug for use as a first-line treatment of ALK-positive patients.

Lung cancer is a considerable health burden for Scotland with incidence rates that are among the highest in the world – it accounted for 25% of the country's cancer deaths in 2014.

Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy sufferers.

Article by
Adam Hill

11th July 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics